Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 3, 2004, Pages 239-252

  Kotler, Donald P ^a   Muurahainen, Norma ^b   Grunfeld, Carl ^c   Wanke, Christine ^d   Thompson, Melanie ^e   Saag, Michael ^f   Bock, Daena ^b   Simons, Gregg ^g   Gertner, Joseph M ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b EMD SERONO INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e AIDS Research Consortium of Atlanta   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g Quality Clinical Research Center   (United States)

Author keywords

Cholesterol; Dyslipidemia; Growth hormone; HIV AIDS; Lipodystrophy; Metabolic

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ADIPOSE TISSUE; ADULT; ARTHRALGIA; ARTICLE; BODY COMPOSITION; CARPAL TUNNEL SYNDROME; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; FEMALE; FOOD AND DRUG ADMINISTRATION; GLUCOSE METABOLISM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPESTHESIA; INSULIN METABOLISM; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUICIDE ATTEMPT;

ADIPOSE TISSUE; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CHOLESTEROL; CONTINENTAL POPULATION GROUPS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMAN GROWTH HORMONE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; PLACEBOS; REPRODUCIBILITY OF RESULTS; VISCERA;

EID: 1442324033     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200403010-00004     Document Type: Article

References (67)

1. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
2. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
3. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr. 2002;31:257-275.
4. Leow MKS, Addy CL, Mantzoros CS. Human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J Clin Endocrinol Metab. 2003;88:1961-1976.
5. Chen D, Misra A, Garg A. Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab. 2002;87:4845-4856.
6. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
7. Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16:413-417.
8. Mann M, Piazza-Hepp T, Koller E, et al. Unusual distributions of body fat in AIDS patients: a review of adverse events reported to the food and drug administration. AIDS Patient Care STDS. 1999;13:287-295.
9. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546-550.
10. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444.
11. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31(Suppl):S140-S144.
12. Lamarche B. Abdominal obesity and its metabolic complications: implications for the risk of ischaemic heart disease. Coron Artery Dis. 1998;9: 473-481.
13. Esposito K, Nicoletti G, Giugliano D. Obesity, cytokines and endothelial dysfunction: a link for the raised cardiovascular risk associated with visceral obesity. J Endocrinol Invest. 2002;25:646-649.
14. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
15. Fessel WJ, Follansbee SE, Rego J. High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions. Implications for pathogenesis of fat redistribution. AIDS. 2002;16:1785-1789.
16. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis. 2001;32:130-139.
17. Kuritzkes DR, Currier J. Cardiovascular risk factors and antiretroviral therapy. N Engl J Med. 2003;348:679-680.
18. Saag MS, Powderly WG, Schambelan M, et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection. Summary of selected trials. Top HIV Med. 2002;10:47-51.
19. Roubenoff R, Weiss L, McDermott A, et al. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS. 1999;13:1373-1375.
20. Roubenoff R, Schmitz H, Bairos L, et al. Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis. 2002;34:390-393.
21. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2496.
22. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
23. Bengtsson BÅ, Edén S, Lönn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76:309-317.
24. Ezzat S, Fear S, Gaillard R-C, et al. Gender-specific responses of lean body composition and non-gender-specific cardiac function improvement following GH replacement in GH-deficient adults. J Clin Endocrinol Metab. 2002;87:2725-2733.
25. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 2001;86:504-510.
26. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab. 1997;82:727-734.
27. Torres RA, Unger KW, Cadman JA, et al. Recombinant human growth hormone improves truncal adiposity and buffalo humps' in HIV-positive patients on HAART. AIDS. 1999;13:2479-2492.
28. Wanke C, Gerrior J, Kantaros J, et al. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV AIDS. 1999;13:2099-2103.
29. Mauss S, Wolf E, Jaeger H. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Ann Intern Med. 1999;131:313-314.
30. Nguyen QV, Malinverni R, Furrer H. Treatment of HAART associated fat accumulation disease with recombinant human growth hormone: results of a randomised double blind placebo controlled crossover trial [abstract LbPp114]. Presented at the XIII International AIDS Conference, Durban, South Africa, July 2000.
31. Richmond G, Appleby V, Strawbridge T. The use of recombinant human growth hormone for dorsocervical fat pad accumulation in a patient on highly active antiretroviral therapy. Presented at the 14th Annual Conference, Association of Nurses in AIDS Care, Chicago, December 2001.
32. Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001; 86:3480-3487.
33. Engelson ES, Glesby MJ, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 2002;30:379-391.
34. Schambelan M, Mulligan K, Grunfeld C, et al. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Ann Intern Med. 1996;125:873-882.
35. Daar E, Gertner J, Kotler D, et al. Recombinant human growth hormone (r-hGH) is effective in the treatment of HIV/AIDS-associated wasting in the era of highly active anti-retroviral therapy (HAART). Presented at the XIV International AIDS Conference, Barcelona, Spain, July 2002.
36. Thompson M, Kotler D, Turner R, et al. Recombinant human growth hormone (rHGH) enhances patient-reported body image and improves quality of life in HARS (HIV-associated adipose redistribution syndrome) [abstract 712]. Presented at the Second International AIDS Pathogenesis and Treatment Conference, Paris, France, July 2003.
37. Molarius A, Seidell JC. Selection of anthropometric indicators for classification of abdominal fatness a critical review. Int J Obes Relat Metab Disord. 1998;22:719-727.
38. Larsson B, Svardsudd K, Welin L, et al. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ. 1984;288: 1401-1404.
39. Kotler DP, Thea DM, Heo M, et al. Relative influences of sex, race, environment, and HIV infection on body composition in adults. Am J Clin Nutr. 1999;69:432-439.
40. Kotler DP, Rosenbaum K, Wang J, et al. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr. 1999;20:228-237.
41. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1997;20:1183-1197.
42. Hochberg Y, Tamhane AC. Step-down procedures. In: Multiple Comparison Procedures. New York: John Wiley & Sons; 1987:53-71.
43. Lipid Guidelines Committee. The American Association of Clinical Endocrinologists. AACE medical guidelines for clinical practice for the diagnosis and treatment of dyslipidemia and prevention of atherogenesis. Endocr Pract. 2000;6:162-213.
44. Kotler D, Engelson E, Heymsfield S, et al. Anthropometric criteria define visceral fat excess in patients with HIV-associated adipose redistribution syndrome (HARS) a subset of HIV lipodystrophy. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002.
45. Pond CM. Paracrine interactions of mammalian adipose tissue. J Exp Zool. 2003;295A:99-110.
46. Despres J-P. Obesity and lipid metabolism: relevance of body fat distribution. Curr Opin Lipidol. 1991;2:5-15.
47. Pouliot M-C, Després J-P, Nadeau A, et al. Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes. 1992;41:826-834.
48. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans. A randomized, placebo-controlled study. AIDS. 2002;16(Suppl):F1-F8.
49. Gelato MC, Mynarcik DC, Quick JL, et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone. A pilot study. J Acquir Immune Defic Syndr. 2002;31:163-170.
50. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy. A randomized, controlled, open-label, multicentre study. AIDS. 2001;15:1811-1822.
51. Miller KD, Jones E, Yanovski JA, et al. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-875.
52. Fujioka S, Matsuzawa Y, Tokunaga K, et al. Contribution of intraabdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism. 1987;36:54-59.
53. Clemmons DR, Snyder DK, Williams R, et al. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects. J Clin Endocrinol Metab. 1987;64:878-883.
54. Tomlinson JW, Crabtree N, Clark PMS, et al. Low-dose growth hormone inhibits 11β-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J Clin Endocrinol Metab. 2003; 88:2113-2118.
55. Pi-Sunyer X. A clinical view of the obesity problem. Science. 2003;299: 859-860.
56. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37(5): 613-620.
57. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97: 1453-1460.
58. Hadigan C, Borgonha S, Rabe J, et al. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism. 2002;51:1143-1147.
59. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr. 2000;25:312-321.
60. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab. 1998;83:382-395.
61. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. Diabetes Care. 2003; 26:16-23.
62. Saint-Marc T, Touraine J-L. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS. 1999;13:1000-1002.
63. Walli R, Michl GM, Mühlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med. 2000;199:253-262.
64. Hadigan C, Yawetz S, Thomas A, et al. A randomized, double-blind, placebo-controlled study of rosiglitazone for patients with HIV lipodystrophy. Presented at the Fifth International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Paris, France, July 2002;B:L12.
65. Martinez E, Domingo P, Perez-Cuevas JB, et al. A randomized, double-blind, placebo-controlled, comparative study on the effects of metformin or gemfibrozil in lipodystrophic HIV-1-infected patients receiving protease inhibitors (Pl). Presented at the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 2002.
66. Yki-Järvinen H, Sutinen J, Silveira A, et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol. 2003;23:688-694.
67. Calmy A, Hirschel B, Hans D, et al. Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy. AIDS. 2003;17: 770-772.